NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that it is investigating the Board of Directors of TriVascular Technologies, Inc. (NASDAQ:TRIV) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop TriVascular Technologies to maximize shareholder value before agreeing to be acquired by Endologix, Inc. (NASDAQ:ELGX).
If you would like to join the action, go to the firm’s website at http://rosenlegal.com/cases-765.html or contact Phillip Kim or Kevin Chan toll-free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com. There is no cost or obligation to you.
Under the terms of the proposed transaction, shareholders will receive a combination of cash and stock to be determined at the closing of the merger, which is currently valued at approximately $9.10 per share. The proposed transaction is valued at approximately $211 million. The investigation relates to whether the proposal is fair to the public shareholders of TriVascular Technologies and whether TriVascular Technologies’ Board breached its fiduciary duties in connection with the proposed sale.
If you currently own shares of TriVascular Technologies and wish to obtain additional information, please visit the firm’s website at http://rosenlegal.com/cases-765.html. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.